看过来，不适合手术的III期肺癌免费好药
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">肺癌的发病率和死亡率是非常高的，肺癌<span style="color: black;">通常</span><span style="color: black;">按照</span>病灶、淋巴结转移、远处脏器转移<span style="color: black;">状况</span>，分为四期。其中III期肺癌指中晚期肺癌，III期有分为IIIA期、IIIB期和IIIC期。除去IIIA期肺癌有手术机会，其他III期肺癌<span style="color: black;">常常</span>只能进行同步放化疗。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">此刻</span>有了免疫治疗，III期肺癌<span style="color: black;">倘若</span><span style="color: black;">不可</span>进行手术治疗，<span style="color: black;">能够</span><span style="color: black;">经过</span>放化疗与免疫治疗联合，<span style="color: black;">这般</span><span style="color: black;">能够</span>给<span style="color: black;">病人</span>带来<span style="color: black;">很强</span>的<span style="color: black;">存活</span>获益。<span style="color: black;">此刻</span>这一个三期临床<span style="color: black;">实验</span>，<span style="color: black;">经过</span>将PD-1<span style="color: black;">控制</span>剂帕博利珠单抗，联合同步放化疗，<span style="color: black;">而后</span>序贯<span style="color: black;">运用</span>帕博利珠单抗与PARP<span style="color: black;">控制</span>剂奥拉帕利联合（奥拉帕利<span style="color: black;">能够</span>阻断肿瘤细胞的基因的错配修复），有望给III期肺癌带来<span style="color: black;">有些</span>新的治疗机会。</p>
<div style="color: black; text-align: left; margin-bottom: 10px;"><img src="https://pic3.zhimg.com/80/v2-7c1947099158ae5defdf4746e927e6ae_720w.webp" style="width: 50%; margin-bottom: 20px;"></div><span style="color: black;">照片</span><span style="color: black;">源自</span>：摄图网<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">这个临床<span style="color: black;">实验</span>招募的是不可切除的局部晚期、III期的非小细胞肺癌<span style="color: black;">病人</span>，临床<span style="color: black;">实验</span>是一项三期临床<span style="color: black;">实验</span>，入组<span style="color: black;">病人</span>比较多，全国多个中心<span style="color: black;">能够</span>申请入组。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">参加本临床<span style="color: black;">科研</span>，您<span style="color: black;">能够</span>搜索下载癌度app，点击临床<span style="color: black;">实验</span>报名，<span style="color: black;">亦</span><span style="color: black;">能够</span>点击下面的链接报名。</p>
<div style="color: black; text-align: left; margin-bottom: 10px;"><a style="color: black;"><span style="color: black;"><span style="color: black;"><span style="color: black;">没</span>癌社区(<span style="color: black;">网</span>名<span style="color: black;">叫作</span>-主<span style="color: black;">重要</span>词或一句含有主<span style="color: black;">重要</span>词的描述)</span><span style="color: black;"><span style="color: black;"></span>www.cancer-free.cn</span></span></a>/application/goType=application<span style="color: black;"><img src="https://pic4.zhimg.com/v2-b595a02448bbc3087a6371047825939b_120x160.jpg" style="width: 50%; margin-bottom: 20px;"></span></div>
<h2 style="color: black; text-align: left; margin-bottom: 10px;"><span style="color: black;">1、</span>入组<span style="color: black;">需求</span></h2>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">1、<span style="color: black;">身患</span>病理学确诊的非小细胞肺癌。 </p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">2、临床分期为IIIA、IIIB或IIIC期。 </p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">3、经<span style="color: black;">太多</span>学科会诊，<span style="color: black;">病人</span><span style="color: black;">不可</span>接受根治性手术。 </p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">4、经过PET-CT以及胸部、腹部、骨盆和脑部的有诊断质量的CT或MRI扫描中，<span style="color: black;">无</span>转移<span style="color: black;">疾患</span>的证据<span style="color: black;">表示</span>为IV期非小细胞肺癌。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">5、<span style="color: black;">身患</span><span style="color: black;">按照</span>RECIST 1.1定义的可<span style="color: black;">测绘</span><span style="color: black;">疾患</span>，<span style="color: black;">最少</span>有一个病灶适合<span style="color: black;">做为</span>靶病灶。 </p>
<h2 style="color: black; text-align: left; margin-bottom: 10px;"><span style="color: black;">2、</span>不适用本<span style="color: black;">科研</span>的排除标准</h2>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">1、<span style="color: black;">身患</span>小细胞肺癌或存在小细胞<span style="color: black;">成份</span>的混合肿瘤。</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">2、<span style="color: black;">拥有</span>MDS/AML的病史、当前诊断<span style="color: black;">或</span>有提示这些<span style="color: black;">疾患</span>。 </p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">3、在过去3个月内有体重下降大于10%（自基线）的记录。 </p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">4、接受过既往胸部放疗，<span style="color: black;">包含</span>食管、纵隔或乳腺癌放疗。</p>
页:
[1]